CatalYm

Executive Summary

CatalYm is a private German biotech developing Visugromab (CTL-002), a monoclonal antibody targeting GDF-15, a key resistance mechanism in solid tumors. By neutralizing GDF-15, the therapy aims to restore anti-tumor immune responses and overcome resistance to checkpoint inhibitors and other treatments. The company’s lead candidate is in Phase 2 trials for multiple solid tumor indications, including non-small cell lung cancer (NSCLC) and urothelial carcinoma, with promising early signals of efficacy and safety. CatalYm’s approach addresses a high unmet need in cancers that are refractory to current immunotherapies, positioning it as a potential first-in-class therapy if successful. With a novel mechanism and a clear scientific rationale, CatalYm has attracted interest from top-tier investors. The upcoming Phase 2 data readouts are pivotal for de-risking the program and demonstrating clinical benefit. A successful outcome could trigger partnership interest from larger pharma companies looking to expand their oncology portfolios. The company’s near-term focus is on advancing its ongoing trials and potentially initiating a registrational study. CatalYm represents a high-risk, high-reward opportunity in the immunotherapy space, with significant upside if Visugromab can validate GDF-15 as a therapeutic target.

Upcoming Catalysts (preview)

• H2 2026Phase 2 Data Readout in NSCLC or Urothelial Carcinoma60% success
• 2026Strategic Partnership or Licensing Deal40% success
• 2026FDA Fast Track or Breakthrough Therapy Designation50% success